Krzysztof Landa CEO CEO of MedInvest Scanner, the President of Meritum L.A. Ltd., a company dealing with market access, pricing and reimbursement, due diligence and actuary for complementary health insurance. As the Deputy Minister of Health in 2015-2017 was responsible for drug policy, reimbursement and prices of medical devices, mapping of health needs, investments in health care, prices of health services and the basic benefits package.  The Founder and President of Watch Health Care Foundation (www.WatchHealthCare.eu), the General Partner in HTA Audit (company dealing with quality of HTA reports before they are submitted to authorities and public institutions); the expert on health care systems of Business Centre Club. Former President of the Central & Eastern European Society of Technology Assessment in Health Care (www.CEESTAHC.org). In 2006-2007 Kris Landa was the Director of Drug Policy Department at the Central Office of National Health Fund in Poland. In 2004 Krzysztof Landa was elected to the Board of Directors of Health Technology Assessment International (HTAi) and performed his duties till mid 2007. He was the Chairman of LOC of the first HTAi Annual Conference in 2004, held in Krakow. 

Kris Landa is a graduate of the University School of Medicine and received his management education at the Postgraduate School of Public Health of Jagiellonian University in Krakow. In 1997-98 he worked for the Harvard-Jagiellonian Consortium for Health in Krakow. From 1998 to 2002 he directed the Bureau for the Standardisation of Medical Practice at the National Center for Quality Assessment in Health Care (NCQA), a governmental institution. 

Promotion of HTA in the region of CEE resulted in international cooperation in education and HTA. Kris Landa organized many national and international HTA workshops and conferences. In years 2006-2008 he provided consultancy for the Serbian Ministry of Health and in 2011-2013 in Ukraine. He was team leader of the World Bank project aimed at introduction of HTA in Serbia, implementation of EBHC principles to the management of basic benefit package and designing a governmental HTA Agency. 

Magdalena Wladysiuk Board Member Magdalena Wladysiuk is the Vice President of HTA Consulting, President of CEESTAHC Society. In HTA Consulting, she is responsible for the strategic development of the company through research and services development, new product launch and marketing. Ms. Wladysiuk main and primary aim is to provide high quality information or data based on evidence based medicine or health technology assessment methodology not only in Poland but in Europe and Asia. Key role of her work is to improve patient outcomes through better healthcare decisions. HTA Consulting provides wide scope of service to planning, collecting, analyzing and presenting clinical, cost data, health technology assessment report to public and private sector - healthcare professionals, payers, hospitals, and employers.

In CEESTAHC she was responsible for the establishing and providing wide connection platform for discussion for all stakeholders in health care system. CEESTAHC mission is to improve the quality of health care systems value with the use of evidence.

• Graduate of the Medical Academy in Lublin in 2000
• MBA and economy in Kozminski Academy in Warsaw in 2004
• Founder of the CEESTAHC in 2003 and its President up to 2005 and from 2010 again the President of CEESTAHC
• Member of HTAi Annual Meeting in 2006-2008
• Ph.D. Program from 2011 in Medical Academy in Lublin

Mitchell Sugarman Board Member Mitchell Sugarman is the Vice President of Global Health Economics, Policy and Payment for Medtronic’s CardioVascular Division. In this role, he is responsible for ensuring that reimbursement is a consideration in every functional area from product conception, through research and development, clinical and regulatory affairs, product launch and marketing. Mr. Sugarman’s primary objective is to ensure that providers and payers (public and private, domestic and foreign) have the right information in order to make appropriate coding, coverage and payment decisions about health care. Key to this role is ensuring that clinical trials are designed with an eye towards providing quality data to health care decision makers rather than just achieving regulatory approval. Medtronic’s CardioVascular Division produces coronary and biliary stents, balloons, wires, aortic stent-grafts and other products used in the treatment and diagnosis of vascular disease and hypertension.

Prior to joining Medtronic, Mr. Sugarman worked at Kaiser Permanente for 19 years initially as the Director of a clinical genetics department, and later as the Director of Medical Technology Assessment. This position involved tracking new drugs, devices and procedures as they moved from experimental to non-experimental, and determining whether they should be part of the medical armamentarium. Critical issues evaluated included safety, efficacy and cost-effectiveness.

Having worked on both the payer/provider side of health care at Kaiser Permanente, and the industry side at Medtronic, Inc., Mr. Sugarman has a unique perspective on health technology assessment and the need to use this discipline in a practical effective manner.

Anna Janczewska-Radwan Board Member For the last 25 years President of Medim Sp. z o.o., one of the largest suppliers of highly specialised medical equipment and devices from Germany, the USA and Great Britain for Polish hospitals.

Graduate of the University of Economics in Katowice.
Founder of the „Endoexpert” Academy of Minimally Invasive Surgery.
Since April 2012 the shadow minister of healthcare in the Shadow Cabinet of Business Centre Club.
In 1991 awarded with the First Lady of Polish Business title and in 1997 - Businesswoman 1997.

Anna Janczewska-Radwan:

• Between 2008 and 2014 President of the Polish Chamber of Medical Products POLMED Currently Vice-president
• Between 2004 and 2008 member of the Public Procurement Council for the President of the Polish Public Procurement Office
• Member of the Tripartite Branch Unit for Healthcare at the Polish Ministry of Health
• Vicepresident of the Workgroup for Innovation Association
• Member of the Programme Council of the Healthcare Forum at the Economic Forum at Krznica Zdrój
• Member of the Health Committee at the National Chamber of Commerce
• Business Centre Club member since 1993, expert on healthcare
• Member of the BCC Healthcare Committee
• Programme Council member for the European Medical Congress
• Vicepresident of the Cluster for Modern Medicine Assocation

Jerzy Wysocki Board Member A medical doctor - specialist in anaesthesiology and intensive care. In the past, the Healtheconomics Director and Market Access leader in one of the leading pharmaceutical companies.

Currently, a Healthcare Expert and Sales Director in one of the worldwide IT leading brands.